ENDPOINTS

AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data

2 months ago

News Briefing

Biohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europe

2 months ago

News Briefing

Lilly asks EU regulator to revisit Kisunla; CHMP recommends PTC's PKU drug

2 months ago

News Briefing

Avidicure's $50M seed round; Flagship's new AI company that detects disease

2 months ago

News Briefing

Veraxa makes a SPAC deal; Illumina discloses layoffs

2 months ago

News Briefing

Danaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal terms

2 months ago

News Briefing

Novartis terminates knee pain study; Telix reports brain tumor data

2 months ago

News Briefing

Boehringer's bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M

2 months ago

News Briefing

Argenx’s Vyvgart Hytrulo syringe is approved in the US; Opthea to cut 65% of staff

3 months ago

News Briefing

Idorsia’s blood pressure pill no longer requires a REMS; Solu raises $41M

3 months ago

News Briefing

Rallybio ends development in rare disorder; ImmunityBio raises $75M

3 months ago

News Briefing

Lexeo discloses new data for heart drug; Spark Therapeutics to lay off workers

3 months ago

News Briefing

Sarepta indicates it's safe to continue Elevidys dosing in Europe; Epsilogen buys TigaTx

3 months ago

News Briefing

Roche says Ocrevus failed Phase 3 study; Sanofi licenses autoimmune asset from Nurix

3 months ago

News Briefing

Prazer Therapeutics raises $20M; Carisma lets go of most staff

3 months ago

News Briefing

LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drug

3 months ago

News Briefing

DBV’s financing for peanut allergy patch; Eisai divests proton pump inhibitor in China

3 months ago

News Briefing

Nkarta to lay off 34% of staff; Savara’s debt financing deal

3 months ago

News Briefing

Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer

3 months ago

News Briefing

Cassava ends work on Alzheimer's drug; Alumis gets $40M upfront from Kaken

3 months ago

News Briefing

Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund

3 months ago

News Briefing

Genfit's up to €185M royalty deal; J&J’s Tremfya gets a Crohn's approval

3 months ago

News Briefing

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion's board

3 months ago

Peer Review

Elevation Oncology stops work on ADC, lays off workers; AstraZeneca’s CEPI funding

3 months ago

News Briefing

about the author

author articles

AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data

Biohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europe

Lilly asks EU regulator to revisit Kisunla; CHMP recommends PTC's PKU drug

Avidicure's $50M seed round; Flagship's new AI company that detects disease

Veraxa makes a SPAC deal; Illumina discloses layoffs

Danaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal terms

Novartis terminates knee pain study; Telix reports brain tumor data

Boehringer's bispecific pact with Cue Biopharma; HepaRegeniX raises €21.5M

Argenx’s Vyvgart Hytrulo syringe is approved in the US; Opthea to cut 65% of staff

Idorsia’s blood pressure pill no longer requires a REMS; Solu raises $41M

Rallybio ends development in rare disorder; ImmunityBio raises $75M

Lexeo discloses new data for heart drug; Spark Therapeutics to lay off workers

Sarepta indicates it's safe to continue Elevidys dosing in Europe; Epsilogen buys TigaTx

Roche says Ocrevus failed Phase 3 study; Sanofi licenses autoimmune asset from Nurix

Prazer Therapeutics raises $20M; Carisma lets go of most staff

LifeMine’s restructuring; Europe won’t renew authorization for PTC’s Duchenne drug

DBV’s financing for peanut allergy patch; Eisai divests proton pump inhibitor in China

Nkarta to lay off 34% of staff; Savara’s debt financing deal

Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer

Cassava ends work on Alzheimer's drug; Alumis gets $40M upfront from Kaken

Surrozen raises $175M, to focus on ophthalmology; CBC Group has a new $1B fund

Genfit's up to €185M royalty deal; J&J’s Tremfya gets a Crohn's approval

BridgeBio, Editas finance chiefs depart; Former FDA No. 2 joins Recursion's board

Elevation Oncology stops work on ADC, lays off workers; AstraZeneca’s CEPI funding